Celgene Corp. offered tantalizing morsels from its phase Ib study of oral GED-0301 (mongersen) in patients with active Crohn's disease, but the tidbits only prompted speculation about the bigger picture behind the curtain of silence. Interim top-line data from the randomized, double-blind, multicenter, exploratory study showed endoscopic improvement (defined as a 25 percent improvement from baseline) "in a proportion of patients treated with oral GED-0301," according to the company, along with clinical response and remission across all treatment groups at week 12.